A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia

被引:377
作者
Arinami, T [1 ]
Gao, M [1 ]
Hamaguchi, H [1 ]
Toru, M [1 ]
机构
[1] TOKYO MED & DENT UNIV,SCH MED,TOKYO 113,JAPAN
关键词
STRUCTURAL POLYMORPHISM; MOLECULAR VARIANT; LINKAGE; CELLS; DIFFERENTIATION; NEUROLEPTICS; D2-RECEPTORS; ALCOHOLISM; EXPRESSION; MUTATION;
D O I
10.1093/hmg/6.4.577
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An excess dopaminergic activity may be implicated in the etiology of schizophrenia. Our objective was to identify nucleotide variants in the 5' region of the dopamine D2 receptor gene (DRD2) and to clarify their effects on schizophrenia. We identified two polymorphisms, the A-241G and -141C Ins/Del, by examination of 259 bp in the 5'-flanking region and 249 bp of exon 1 of DRD2, Reporter constructs containing the -141C Del allele cloned into a luciferase reporter plasmid drove 21% (Y-79 cells) and 43% (293 cells) expression compared with the -141C Ins allele, In a case-control study, the -141C Del allele frequency was significantly lower in 260 schizophrenic patients than in 312 controls (OR = 0.60, 95% CI 0.44-0.81, P<0,001), No significant association was found between the A-241G polymorphism and in vitro luciferase activity, or in allele frequency between the patients versus controls, These findings show that the -141C Ins/Del may be a functional polymorphism in the 5'-promoter region of DRD2 and may affect the susceptibility to schizophrenia.
引用
收藏
页码:577 / 582
页数:6
相关论文
共 34 条
[1]   RECEPTOR ACTIVITY AND TURNOVER OF DOPAMINE AND NORADRENALINE AFTER NEUROLEPTICS [J].
ANDEN, NE ;
BUTCHER, SG ;
CORRODI, H ;
FUXE, K ;
UNGERSTEDT, U .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1970, 11 (03) :303-+
[2]  
Arinami T, 1996, AM J MED GENET, V67, P133, DOI 10.1002/(SICI)1096-8628(19960409)67:2<133::AID-AJMG2>3.3.CO
[3]  
2-X
[4]   ASSOCIATION OF DOPAMINE D2 RECEPTOR MOLECULAR VARIANT WITH SCHIZOPHRENIA [J].
ARINAMI, T ;
ITOKAWA, M ;
ENGUCHI, H ;
TAGAYA, H ;
YANO, S ;
SHIMIZU, H ;
HAMAGUCHI, H ;
TORU, M .
LANCET, 1994, 343 (8899) :703-704
[5]  
ASHERSON P, 1994, LANCET, V343, P1045
[6]   THE HUMAN DOPAMINE D5 RECEPTOR GENE - CLONING AND CHARACTERIZATION OF THE 5'-FLANKING AND PROMOTER REGION [J].
BEISCHLAG, TV ;
MARCHESE, A ;
MEADORWOODRUFF, JH ;
DAMASK, SP ;
ODOWD, BF ;
TYNDALE, RF ;
VANTOL, HHM ;
SEEMAN, P ;
NIZNIK, HB .
BIOCHEMISTRY, 1995, 34 (17) :5960-5970
[7]   DOPAMINE RECEPTOR-BINDING PREDICTS CLINICAL AND PHARMACOLOGICAL POTENCIES OF ANTI-SCHIZOPHRENIC DRUGS [J].
CREESE, I ;
BURT, DR ;
SNYDER, SH .
SCIENCE, 1976, 192 (4238) :481-483
[8]   STRUCTURE AND LINKAGE OF THE D2 DOPAMINE RECEPTOR AND NEURAL CELL-ADHESION MOLECULE GENES ON HUMAN CHROMOSOME-11Q23 [J].
EUBANKS, JH ;
DJABALI, M ;
SELLERI, L ;
GRANDY, DK ;
CIVELLI, O ;
MCELLIGOTT, DL ;
EVANS, GA .
GENOMICS, 1992, 14 (04) :1010-1018
[9]   INDUCTION OF ADENYLATE-CYCLASE SENSITIVE DOPAMINE D2-RECEPTORS IN RETINOIC ACID-INDUCED DIFFERENTIATED HUMAN NEUROBLASTOMA SHSY-5Y CELLS [J].
FAROOQUI, SM .
LIFE SCIENCES, 1994, 55 (24) :1887-1893
[10]  
FILTZ TM, 1993, MOL PHARMACOL, V44, P371